videoSlug

VideoSlug_VideoQuery

slug

VideoPageContentQuery

content

videos

query VideoSlug_VideoQuery(
  $videoSlug: String!
) {
  ...VideoPageContentQuery_1X4EH4
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment LatestVideos_Videos on Query {
  videos(first: 5, upcoming: false, order: {field: liveTime, direction: DESC}) {
    edges {
      node {
        id
        title
        lang
        pageUrl
        liveTime
        isLive
        companies {
          name
          squareLogoUrl
          id
        }
      }
    }
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment VideoPageContentQuery_1X4EH4 on Query {
  content(slug: $videoSlug, type: [VIDEO, WEBCAST]) {
    __typename
    id
    title
    slug
    lang
    htmlBody
    isPremium
    companies {
      viewerIsFollowing
      id
      name
      pageUrl
      defaultInstrument {
        id
        isin
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    createdAt
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    ... on Video {
      imgUrl
      videoEmbedUrl(location: "inderes")
      audioEmbedUrl
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ... on Webcast {
      imgUrl
      videoEmbedUrl(location: "inderes")
      registrationInfoHtml
      registrationUrl
      liveTime
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
  }
  ...LatestVideos_Videos
}


type

__typename

title

lang

htmlBody

isPremium

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

first

order

upcoming

edges

ExpreS2ion Biotech Holding

ExpreS2ion Biotechnologies will release its Q1 results on 16 May 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies’ CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event.

ExpreS2ion Biotechnologies will release its Q1 results on 16 May 2024. Later the same day at 10:00, ExpreS2ion Biotechnologies&#x2019; CEO Bent U. Frandsen and CFO Keith Alexander will take a deeper dive into the results and achievements in a virtual live event. ExpreS2ion Biotechnologies has commenced 2024 equipped with a clear new strategic direction of leveraging their platform to advance assets with shorter development timelines and less costly paths to value creation, and a solid Phase III validation of its ExpreS2&#x2122; antigen production system. The potential in the pipeline has further been validated during 2024, with completion of GLP safety study for ES2B-C001 (HER2-VLP) breast cancer vaccine candidate. This could be the focal point in the Q1 2024 reporting. ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system. Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 11:15, 18 April 2024.

HC Andersen Capital

ExpreS2ion Biotechnologies - Presentation of Q1 Report 2024

Orion

Orion as an Investment | Life Science Night Dec. 9, 2025

Citycon

Kojamo

Asuntosalkku

Investors House

Toivo Group

Ovaro Kiinteistösijoitus

Cityvarasto

Kiinteistösektori sijoituskohteena | Kiinteistöilta 3.12.2025

Panostaja

Panostaja: Pöytä putsattu Hyggan osalta

Ilkka

Ilkka: Takaisku sijoitustarinalle

Kesko

Tokmanni Group

Puuilo

Verkkokauppa.com

Katsaus kaupan alan yhtiöihin

Viimeisimmät videot